Safety, Tolerability and PK/PD of KMRC011 in Healthy Volunteers

Phase 1, randomised, single-blind trial of KMRC011 in Acute Radiation Syndrome (ARS) (5 arms), sponsored by iNtRON Biotechnology. Primary endpoints: Number of subjects with treatment-emergent adverse event or adverse drug reaction up to 7 days, Number of subjects with clinically significant changes in hematology test result up to 7 days and 16 more. Started Jun 2018; status: completed.